Thursday, September 03, 2020 9:33:52 AM
Progressing planned pre-clinical testing for innovative allogeneic MSC-based cellular therapy for both COVID-19 and aGVHD
FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform. Avalon plans to develop the MSC platform as a potential therapy for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and for bone marrow transplant related complications of acute graft versus host disease (aGVHD).
Mesenchymal stromal cells are typically isolated from the bone marrow, umbilical cord blood, fat tissue and other tissue types. MSCs possess unique qualities including anti-inflammatory and immunomodulatory activities. MSCs have multiple functions within the immune system, affecting many different immune cell types. MSCs have the ability to suppress T-cell proliferation, cytokine secretion and regulate the balance of antibody-based and cell-based immune responses. MSCs are capable of inhibiting the activation of dendritic cells and blocking the ability of dendritic cells to present antigens to other cells in the immune system. MSCs can also tone down the abnormal release of either antibodies from B-cells or cytokines from natural killer cells.
Avalon’s MSC therapeutic platform represents the culmination of extensive research and development that leverages the Company’s scientific and clinical expertise in cellular therapy and stem cell-derived exosome (ACTEXTM) applications. Avalon believes that this allogeneic MSC platform could offer a unique and efficacious approach to treat the potentially fatal acute respiratory distress syndrome, multi-system inflammatory syndrome and cytokine storm related to severe cases of COVID-19.
Accumulating evidence has revealed that aberrant and excessive immune responses evoked by a SARS-CoV-2 virus infection are involved in lung damage and multi-organ injury seen in some patients with moderate and severe COVID-19. Also involving an excessive immune assault on multiple organs and tissues, including the gut, liver and skin, aGVHD is a medical complication that is potentially life-threatening and commonly seen in allogeneic bone marrow transplantation. There are currently no effective therapies for the prevention and treatment of aGVHD.
The Company is currently progressing its planned pre-clinical testing for its MSC therapeutic platform for COVID-19 and aGVHD, with plans to initiate a first-in-human clinical study during the first half of 2021, assuming clearance from U.S. and/or non-U.S. regulatory agencies.
“Taking advantage of our expertise in cellular therapy development, we are encouraged by the rapid progress we have made in moving our MSC technology platform towards the clinic for these two important indications,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “We look forward to providing updates on our advancements.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
"It never was my thinking that made the big money for me. It always was the sitting. Got that? My sitting tight!" - Reminiscences of a Stock Operator -
Recent ALBT News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:31:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 09:01:50 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/15/2024 08:05:29 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:29:00 PM
- Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 12:18:14 PM
- Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us • GlobeNewswire Inc. • 07/18/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 12:37:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:05:13 PM
- Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:54:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 09:10:10 PM
- Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report • GlobeNewswire Inc. • 05/24/2024 09:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 12:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:17 PM
- Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 04/22/2024 01:00:00 PM
- Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:49:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:30:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:30:46 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/20/2023 08:18:23 PM
- Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM